Screener
Viking Therapeutics VKTX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Accounts payable | $67,183 | $53,251 |
| Other accrued liabilities | 39,142 | 23,279 |
| Lease liability, current | — | 137 |
| Total current liabilities | 106,325 | 76,667 |
| Total liabilities | 106,325 | 76,667 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.00001 par value: 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's total current liabilities?
- Viking Therapeutics (VKTX) reported total current liabilities of $106.33M in Q1 2026.
- How has Viking Therapeutics's total current liabilities changed year-over-year?
- Viking Therapeutics's total current liabilities increased by 443.2% year-over-year, from $19.57M to $106.33M.
- What is the long-term trend for Viking Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Viking Therapeutics's total current liabilities has grown at a 44.6% compound annual growth rate (CAGR), from $12.13M to $76.67M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Viking Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude